

SUPPORTING INFORMATION

Edaravone Containing Isoindoline Nitroxides for Potential Treatment of Cardiovascular Ischaemia

James R. Walker,^{a,b} Kathryn E. Fairfull-Smith,^{a,b} Kazunori Anzai,^c Shannen Lau,^d Paul J. White,^d Peter J. Scammells^{a,d} and Steven E. Bottle^{a,b,*}

^aARC Centre of Excellence for Free Radical Chemistry and Biotechnology.

^bChemistry Discipline, Faculty of Science and Technology, Queensland University of Technology, QLD, 4001, Australia. Fax: 61 7 3138 1804; Tel: +61 7 3138 1356; E-mail: s.bottle@qut.edu.au

^cNihon Pharmaceutical University, 10281 Komura, Ina-machi, Kitaaachi-gun, Saitama 362-0806, Japan.

^dMedicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.

Table of contents

Figure S1. 5-(3-Methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7 , EI-mass spectrum.....	S2
Figure S2. 5-(3-Methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7 , analytical HPLC chromatogram	S3
Figure S3. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 , ¹ H NMR spectrum (400 MHz, CDCl ₃)	S4
Figure S4. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 , ¹³ C NMR spectrum (100 MHz, CDCl ₃)	S5
Figure S5. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 , ¹³ C DEPT NMR spectrum (100 MHz, CDCl ₃)	S6
Figure S6. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 , EI-mass spectrum.....	S7
Figure S7. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 , analytical HPLC chromatogram	S8
Figure S8. Comparison of ¹³ C DEPT NMR spectra (100 MHz, CDCl ₃) for 5-(3-methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 and edaravone (3-methyl-1-phenyl-2-pyridazin-5-one) 1	S9

Figure S1. 5-(3-Methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl **7**, EI-mass spectrum




Figure S2. 5-(3-Methyl-pyrazol-5-yl-1-yl)-1,1,3,3-tetramethylisindolin-2-yloxy **7**,
analytical HPLC chromatogram





Figure S3. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10**, ^1H NMR spectrum (400 MHz, CDCl_3)




Figure S4. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10**, ^{13}C NMR spectrum (100 MHz, CDCl_3)




Figure S5. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10**, ^{13}C DEPT NMR spectrum (100 MHz, CDCl_3)




Figure S6. 5-(3-Methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10**, EI-mass spectrum





Figure S7. 5-(3-Methyl-pyrazol-5-yl-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10**, analytical HPLC chromatogram




Figure S8. Comparison of ^{13}C DEPT NMR spectra (100 MHz) for 5-(3-methyl-pyrazol-5-yl-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline **10** and edaravone (3-methyl-1-phenyl-2-pyridazin-5-one) **1** in CDCl_3

